The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia Group
  4. Cochrane Back Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Consumers and Communication Group
  10. Cochrane Cystic Fibrosis and Genetic Disorders Group
  11. Cochrane Dementia and Cognitive Improvement Group
  12. Cochrane Depression, Anxiety and Neurosis Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Ear, Nose and Throat Disorders Group
  16. Cochrane Effective Practice and Organisation of Care Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological Cancer Group
  21. Cochrane Haematological Malignancies Group
  22. Cochrane Heart Group
  23. Cochrane Hepato-Biliary Group
    1. About this group
    2. Reviews
      1. Abdominal lift for laparoscopic cholecystectomyReview
      2. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis BReview
      3. Aminoadamantanes for chronic hepatitis CReview
      4. Aminoadamantanes versus other antiviral drugs for chronic hepatitis CReviewNew
      5. Anabolic-androgenic steroids for alcoholic liver diseaseReview
      6. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patientsReview
      7. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleedingReview
      8. Antibiotic prophylaxis for leptospirosisReview
      9. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatographyReview
      10. Antibiotic prophylaxis for patients undergoing elective laparoscopic cholecystectomyReview
      11. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleedingReview
      12. Antibiotics for leptospirosisReview
      13. Antibiotics for preventing leptospirosisReviewWithdrawn
      14. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patientsReview
      15. Antibiotics for treating leptospirosisReviewWithdrawn
      16. Antibody induction versus corticosteroid induction for liver transplant recipientsReview
      17. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipientsReview
      18. Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseaseReview
      19. Antioxidant supplements for liver diseasesReview
      20. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitisReview
      21. Antioxidant supplements for preventing gastrointestinal cancersReview
      22. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseasesReview
      23. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virusReview
      24. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantationReview
      25. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virusReview
      26. Artificial and bioartificial support systems for liver failureReview
      27. Azathioprine for primary biliary cirrhosisReview
      28. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adultsReview
      29. Bariatric surgery for non-alcoholic steatohepatitis in obese patientsReview
      30. Benzodiazepine receptor antagonists for hepatic encephalopathyReview
      31. Bezafibrate for primary biliary cirrhosisReview
      32. Bicyclol for chronic hepatitis BReview
      33. Bicyclol for chronic hepatitis CReview
      34. Bile acids for liver-transplanted patientsReview
      35. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitisReview
      36. Bile acids for primary sclerosing cholangitisReview
      37. Bile acids for viral hepatitisReview
      38. Bisphosphonates for osteoporosis in primary biliary cirrhosisReview
      39. Booster dose vaccination for preventing hepatitis BReview
      40. Branched-chain amino acids for hepatic encephalopathyReview
      41. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipientsReview
      42. Cardiopulmonary interventions to decrease blood loss and blood transfusion requirements for liver resectionReview
      43. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infectionReview
      44. Chinese medicinal herbs for cholelithiasisReview
      45. Chinese medicinal herbs for chronic hepatitis BReview
      46. Chlorambucil for patients with primary biliary cirrhosisReview
      47. Cholecystectomy deferral in patients with endoscopic sphincterotomyReview
      48. Cholecystectomy for gallbladder polypReview
      49. Cholecystectomy for patients with silent gallstonesReview
      50. Cholecystectomy for suspected gallbladder dyskinesiaReview
      51. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosisReview
      52. Colchicine for primary biliary cirrhosisReview
      53. Cryotherapy for hepatocellular carcinomaReview
      54. Cryotherapy for liver metastasesReview
      55. Cyclosporin A for primary biliary cirrhosisReview
      56. Cyclosporin versus tacrolimus for liver transplanted patientsReview
      57. D-penicillamine for primary biliary cirrhosisReview
      58. D-penicillamine for primary sclerosing cholangitisReview
      59. Day-surgery versus overnight stay surgery for laparoscopic cholecystectomyReview
      60. Dopamine agents for hepatic encephalopathyReview
      61. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisReviewWithdrawn
      62. Early versus delayed laparoscopic cholecystectomy for people with acute cholecystitisReview
      63. Early versus delayed laparoscopic cholecystectomy for uncomplicated biliary colicReview
      64. Elective surgery for benign liver tumoursReview
      65. Electro-coagulation for liver metastasesReview
      66. Emergency sclerotherapy versus vasoactive drugs for bleeding oesophageal varices in cirrhotic patientsReview
      67. Endoscopic balloon sphincter dilation (sphincteroplasty) versus sphincterotomy for common bile duct stonesReview
      68. Endoscopic retrograde cholangiopancreaticography with or without stenting in patients with pancreaticobiliary malignancy, prior to surgeryReview
      69. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsReview
      70. Fewer-than-four ports versus four ports for laparoscopic cholecystectomyReview
      71. Formal education of patients about to undergo laparoscopic cholecystectomyReview
      72. Glucocorticosteroids for primary biliary cirrhosisReview
      73. Glucocorticosteroids for primary sclerosing cholangitisReview
      74. Glucocorticosteroids for viral hepatitis CReview
      75. Hepatitis A immunisation in persons not previously exposed to hepatitis AReview
      76. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothersReview
      77. Hepatitis B immunisation in persons not previously exposed to hepatitis B or with unknown exposure statusReview
      78. Hepatitis B vaccination for patients with chronic renal failureReview
      79. Herbal medicines for fatty liver diseasesReview
      80. Hormone replacement for osteoporosis in women with primary biliary cirrhosisReview
      81. Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesReview
      82. Image-guided percutaneous procedure plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscessReview
      83. Immunoglobulins for preventing hepatitis AReview
      84. Interferon alpha for chronic hepatitis DReview
      85. Interferon for acute hepatitis CReview
      86. Interferon for interferon naive patients with chronic hepatitis CReview
      87. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CReview
      88. Interventions for paracetamol (acetaminophen) overdoseReview
      89. Intraperitoneal local anaesthetic instillation versus no intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomyReview
      90. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusionReview
      91. Ischaemic preconditioning for liver transplantationReview
      92. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantationReview
      93. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinomaReview
      94. Laparoscopic surgical box model training for surgical trainees with limited prior laparoscopic experienceReview
      95. Laparoscopic surgical box model training for surgical trainees with no prior laparoscopic experienceReview
      96. Laparoscopic versus open cholecystectomy for patients with symptomatic cholecystolithiasisReview
      97. Laparoscopic versus open liver resection for benign and malignant hepatic lesions in adultsReview
      98. Laparoscopic versus small-incision cholecystectomy for patients with symptomatic cholecystolithiasisReview
      99. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastasesReview
      100. Low pressure versus standard pressure pneumoperitoneum in laparoscopic cholecystectomyReview
      101. Medicinal herbs for hepatitis C virus infectionReview
      102. Methods of cystic duct occlusion during laparoscopic cholecystectomyReview
      103. Methods of decreasing infection to improve outcomes after liver resectionsReview
      104. Methods of intraperitoneal local anaesthetic instillation for laparoscopic cholecystectomyReview
      105. Methods of preventing bacterial sepsis and wound complications after liver transplantationReview
      106. Methods of vascular occlusion for elective liver resectionsReview
      107. Methods of vascular occlusion for elective liver resectionsReviewWithdrawn
      108. Methods to decrease blood loss and transfusion requirements for liver transplantationReview
      109. Methods to decrease blood loss during liver resection: a network meta-analysisReview
      110. Methotrexate for primary biliary cirrhosisReview
      111. Microwave coagulation for liver metastasesReview
      112. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseasesReview
      113. Miniports versus standard ports for laparoscopic cholecystectomyReview
      114. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinomaReview
      115. Nitazoxanide for chronic hepatitis CReview
      116. Nonabsorbable disaccharides for hepatic encephalopathyReview
      117. Nutritional interventions for liver-transplanted patientsReview
      118. Nutritional support for liver diseaseReview
      119. Open, small-incision, or laparoscopic cholecystectomy for patients with symptomatic cholecystolithiasis. An overview of Cochrane Hepato-Biliary Group reviewsReviewOverview
      120. Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumoursReview
      121. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CReview
      122. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CReview
      123. Pentoxifylline for alcoholic hepatitisReview
      124. Percutaneous cholecystostomy for high-risk surgical patients with acute calculous cholecystitisReview
      125. Percutaneous ethanol injection for liver metastasesReview
      126. Percutaneous needle aspiration, injection, and re-aspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cystsReview
      127. Percutanous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinomaReview
      128. Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular controlReview
      129. Pharmacological interventions for prevention or treatment of postoperative pain in people undergoing laparoscopic cholecystectomyReview
      130. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resectionReview
      131. Pharmacological interventions versus no pharmacological intervention for ischaemia reperfusion injury in liver resection surgery performed under vascular controlReview
      132. Phyllanthus species for chronic hepatitis B virus infectionReview
      133. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infectionReview
      134. Piggy-back graft for liver transplantationReview
      135. Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosisReview
      136. Pre-operative biliary drainage for obstructive jaundiceReview
      137. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitisReview
      138. Probiotics for patients with hepatic encephalopathyReview
      139. Propylthiouracil for alcoholic liver diseaseReview
      140. Prostaglandins for adult liver transplanted patientsReview
      141. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinomaReview
      142. Ribavirin monotherapy for chronic hepatitis CReview
      143. Ribavirin plus interferon versus interferon for chronic hepatitis CReview
      144. Ribavirin with or without alpha interferon for chronic hepatitis CReviewWithdrawn
      145. Robot assistant versus human or another robot assistant in patients undergoing laparoscopic cholecystectomyReview
      146. Routine abdominal drainage for uncomplicated liver resectionReview
      147. Routine abdominal drainage for uncomplicated open cholecystectomyReview
      148. Routine abdominal drainage versus no abdominal drainage for uncomplicated laparoscopic cholecystectomyReview
      149. Routine drainage for orthotopic liver transplantationReview
      150. S-adenosyl-L-methionine for alcoholic liver diseasesReview
      151. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis BReview
      152. Small-incision versus open cholecystectomy for patients with symptomatic cholecystolithiasisReview
      153. Somatostatin analogues for acute bleeding oesophageal varicesReview
      154. Sphincterotomy for biliary sphincter of Oddi dysfunctionReview
      155. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitisReview
      156. Surgical resection versus liver transplant for patients with hepatocellular carcinomaReview
      157. Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastasesReview
      158. Surgical versus endoscopic treatment of bile duct stonesReview
      159. T-tube drainage versus primary closure after laparoscopic common bile duct explorationReview
      160. T-tube drainage versus primary closure after open common bile duct explorationReview
      161. Tamoxifen for hepatocellular carcinomaReview
      162. Techniques for liver parenchymal transection in liver resectionReview
      163. Techniques of flushing and reperfusion for liver transplantationReview
      164. Terlipressin for acute esophageal variceal hemorrhageReview
      165. Terlipressin for hepatorenal syndromeReview
      166. Three dimensional versus two dimensional imaging for laparoscopic cholecystectomyReview
      167. TIPS versus paracentesis for cirrhotic patients with refractory ascitesReview
      168. Transarterial (chemo)embolisation for unresectable hepatocellular carcinomaReview
      169. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastasesReview
      170. Ursodeoxycholic acid and/or antibiotics for prevention of biliary stent occlusionReview
      171. Ursodeoxycholic acid for primary biliary cirrhosisReview
      172. Vaccines for preventing hepatitis B in health-care workersReview
      173. Vascular occlusion for elective liver resectionsReview
      174. Veno-venous bypass versus none for liver transplantationReview
      175. Virtual reality training for surgical trainees in laparoscopic surgeryReview
      176. Vitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver diseasesReview
      177. Weight reduction for non-alcoholic fatty liver diseaseReview
      178. Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomyReview
    3. Protocols
      1. Acupuncture for chronic hepatitis B virus infectionProtocol
      2. Adefovir dipivoxil for chronic hepatitis BProtocol
      3. Adefovir dipivoxil for chronic hepatitis BProtocol
      4. Adefovir dipivoxil versus other antiviral drugs for chronic hepatitis BProtocol
      5. Albumin and other plasma expanders for paracentesis treatment of ascites in cirrhotic patientsProtocol
      6. Anterior approach versus conventional liver resection for hepatocellular carcinomaProtocol
      7. Antibiotic prophylaxis for surgical site infection in patients undergoing liver transplantationProtocol
      8. Antibiotics for cholangitis and/or cholecystitisProtocol
      9. Antibiotics for hepatic encephalopathyProtocol
      10. Antiviral agents for hepatitis B virus-related cirrhosisProtocol
      11. Antiviral treatments for lamivudine-resistant chronic hepatitis B adult patientsProtocol
      12. Banding ligation versus beta-blockers for primary prophylaxis of oesophageal variceal bleeding in childrenProtocol
      13. Beta-blocker plus nitrates for secondary prevention of variceal bleedingProtocol
      14. Beta-blockers alone or with endoscopic therapy for prevention of variceal rebleeding in portal hypertensionProtocol
      15. Beta-blockers for prevention of oesophageal variceal rebleeding in cirrhotic patientsProtocol
      16. Bile acids for biliary colicProtocol
      17. Capsule endoscopy for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      18. Celsior solution versus University of Wisconsin solution in liver preservation for transplantationProtocol
      19. Chemotherapy for gallbladder cancerProtocol
      20. Chinese herbal medicines for adverse events of transarterial chemoembolization in patients with primary liver cancerProtocol
      21. Comparison of medicinal herbs for chronic hepatitis B virus infectionProtocol
      22. Conversion of calcineurin inhibitor treatment to target of rapamycin inhibitor treatment versus continuation of calcineurin inhibitor treatment for liver transplant recipientsProtocol
      23. Diets for primary prevention of gallbladder stones in adultsProtocol
      24. Drug-eluting bead transarterial chemoembolisation for unresectable hepatocellular carcinomaProtocol
      25. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitisProtocol
      26. Emergency sclerotherapy or band ligation combined with vasoactive drugs for bleeding esophageal varices in cirrhosisProtocol
      27. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in patients with portal hypertensionProtocol
      28. Endoscopic interventions for unresectable cholangiocarcinomaProtocol
      29. Entecavir for chronic hepatitis BProtocol
      30. Erythrocytapheresis versus phlebotomy for hereditary haemochromatosisProtocol
      31. Fibrin-based haemostatic agents for reducing blood loss in adult liver resectionProtocol
      32. Foscarnet for chronic hepatitis BProtocol
      33. Glucocorticosteroids for alcoholic hepatitisProtocol
      34. Glucocorticosteroids for infants with biliary atresia following Kasai portoenterostomyProtocol
      35. Glucocorticosteroids for liver transplanted patientsProtocol
      36. Glucocorticosteroids for patients undergoing laparoscopic cholecystectomyProtocol
      37. Glucocorticosteroids for viral hepatitis BProtocol
      38. Glycyrrhizin for chronic hepatitis B virus infectionProtocol
      39. Glycyrrhizin versus antiviral drugs for chronic hepatitis B virus infectionProtocol
      40. Granulocyte-colony stimulating factor for acute liver failure or acute-on-chronic liver failureProtocol
      41. Hepatitis B immune globulin for preventing hepatitis B recurrence after liver transplantationProtocol
      42. Hepatitis B immune globulin for prevention of posttransplantation hepatitis BProtocol
      43. Hepatitis B immunoglobulin during pregnancy for the prevention of mother to child transmission of hepatitis B virusProtocol
      44. Interferon alpha for chronic hepatitis BProtocol
      45. Interferon beta for chronic hepatitis BProtocol
      46. Interferon for hepatocellular carcinomaProtocol
      47. Interferon gamma for chronic hepatitis BProtocol
      48. Intra-peritoneal saline instillation versus no instillation for laparoscopic cholecystectomyProtocol
      49. Isoprinosine for chronic hepatitis BProtocol
      50. Isoprinosine versus other antiviral drugs for chronic hepatitis BProtocol
      51. L-ornithine-L-aspartate for hepatic encephalopathyProtocol
      52. Lamivudine during pregnancy for preventing hepatitis B virus infection in newbornsProtocol
      53. Lamivudine for chronic hepatitis B in adultsProtocol
      54. Lamivudine for preventing reactivation of hepatitis B infection in patients planned to undergo immunosuppressive therapyProtocol
      55. Laparoscopic-endoscopic rendezvous versus preoperative endoscopic sphincterotomy for common bile duct stones in patients undergoing laparoscopic cholecystectomyProtocol
      56. Levamisole for chronic hepatitis BProtocol
      57. Magnetic resonance imaging, computer tomography scan, and oesophagography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      58. Medical therapeutic agents for Wilson's diseaseProtocol
      59. Medical treatments for autoimmune hepatitisProtocol
      60. Medicinal herbs for acute hepatitis BProtocol
      61. Methods of gallbladder dissection for laparoscopic cholecystectomyProtocol
      62. Mycophenolate mofetil for liver-transplanted patientsProtocol
      63. Naloxone for hepatic encephalopathyProtocol
      64. Non-invasive test of liver fibrosis for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      65. Non-steroid anti-inflammatory drugs for biliary colicsProtocol
      66. Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver diseaseProtocol
      67. Organic nitrates for prevention of oesophageal varices bleeding and re-bleedingProtocol
      68. Pegylated interferon for acute hepatitis CProtocol
      69. Pegylated interferon for chronic hepatitis BProtocol
      70. Perfusion techniques for liver retrieval in liver donorsProtocol
      71. Pharmacological interventions for the primary prevention of gallbladder stones in adultsProtocol
      72. Pharmacological interventions to decrease ischaemia reperfusion injury in liver transplantationProtocol
      73. Phlebotomy for hereditary haemochromatosisProtocol
      74. Platelet count, spleen length, and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      75. Postexposure vaccines for hepatitis AProtocol
      76. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinomaProtocol
      77. Preoperative physical exercise training for patients scheduled for major abdominal surgeryProtocol
      78. Prostaglandin E1 analogues for chronic hepatitis BProtocol
      79. Protease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virusProtocol
      80. Selective vasopressin type 2 receptor antagonist for patients with cirrhosisProtocol
      81. Serological laboratory tests for diagnosis of human leptospirosis in patients presenting with clinical symptomsProtocolDiagnostic
      82. Sophorus species for chronic hepatitis B virus infectionProtocol
      83. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhageProtocol
      84. Surgical versus medical treatment of refractory ascitesProtocol
      85. Systemic chemotherapy for inoperable hepatocellular carcinomaProtocol
      86. Techniques of biliary reconstruction for liver transplantationProtocol
      87. Telbivudine for chronic hepatitis BProtocol
      88. Tests for diagnosis of common bile duct stonesProtocolDiagnostic
      89. Thymosin alpha1 for chronic hepatitis BProtocol
      90. Tiopronin for chronic hepatitis BProtocol
      91. Total portosystemic shunt versus shunts preserving portal venous hepatic perfusion for variceal haemorrhageProtocol
      92. Transarterial (chemo)embolisation versus other nonsurgical ablation methods for liver metastasesProtocol
      93. Transient elastography for diagnosis of hepatic fibrosis in people with alcoholic liver diseaseProtocolDiagnostic
      94. Transient ultrasound elastography and magnetic resonance elastography for the diagnosis of oesophageal varices in patients with chronic liver disease or portal vein thrombosisProtocolDiagnostic
      95. Transjugular intrahepatic portosystemic shunts for hepatorenal syndromeProtocol
  24. Cochrane HIV/AIDS Group
  25. Cochrane Hypertension Group
  26. Cochrane Incontinence Group
  27. Cochrane Infectious Diseases Group
  28. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  29. Cochrane Injuries Group
  30. Cochrane Lung Cancer Group
  31. Cochrane Menstrual Disorders and Subfertility Group
  32. Cochrane Metabolic and Endocrine Disorders Group
  33. Cochrane Methodology Review Group
  34. Cochrane Movement Disorders Group
  35. Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  36. Cochrane Musculoskeletal Group
  37. Cochrane Neonatal Group
  38. Cochrane Neuromuscular Disease Group
  39. Cochrane Occupational Safety and Health Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Peripheral Vascular Diseases Group
  43. Cochrane Pregnancy and Childbirth Group
  44. Cochrane Prostatic Diseases and Urologic Cancers Group
  45. Cochrane Public Health Group
  46. Cochrane Renal Group
  47. Cochrane Schizophrenia Group
  48. Cochrane Sexually Transmitted Infections Group
  49. Cochrane Skin Group
  50. Cochrane Stroke Group
  51. Cochrane Tobacco Addiction Group
  52. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  53. Cochrane Wounds Group

SEARCH